Fresh Frozen Facts Part 4: A Thoughtful Look at Plasma Transfusion by Dr. Caitlin Raymond
Caitlin Raymond, MD/PhD shared an insightful chain of posts on LinkedIn:
”Fresh Frozen Facts, Part IV: Beyond the Blood Bag
We’ve spent the last three posts unpacking the nuances of plasma as a transfusion product — thawed, typed, and delivered with varying degrees of clarity and clinical intent. But plasma’s story doesn’t stop there.
In Part IV, we explore what happens after donation — when plasma is fractionated, purified, and turned into targeted biologics that power modern hematology, neurology, rheumatology, immunology, and more.
From albumin for oncotic support to IVIG for immune modulation and Rh immune globulin for alloimmunization prevention, these plasma-derived therapies are more than just “blood products.” They’re precision tools — crafted for specific indications and held to pharmaceutical-grade standards.
We cover:
- Albumin: when it’s the right choice — and when it isn’t
- IVIG: how it works, when to use it, and key risks to know
- RhIg: an elegant triumph of targeted immunotherapy
- Hyperimmune globulins, antithrombin, C1 esterase inhibitor, and more
- The evolving landscape of patient-centered transfusion, including care for Jehovah’s Witnesses and the legacy of hemophilia and HIV
This final installment is about precision, stewardship, and respect — for the science and the people behind every plasma product.
And if you’ve missed the earlier parts of the series, now’s the time to catch up.
Because transfusion medicine doesn’t end with a blood bag — and sometimes the most powerful plasma products don’t look like blood at all.
Read the full post here.
Caitlin Raymond, MD/PhD, has launched an educational series on Fresh Frozen Plasma (FFP), now available on her journal blog.
Enjoy the final part and make sure you do not miss all the Fresh Frozen Facts!
Stay tuned for updates to the Fresh Frozen Facts series on Hemostasis Today.
-
Nov 3, 2025, 08:23The 1st Participant in A New CHECK-NIRS Clinical Study is Enrolled!
-
Nov 3, 2025, 08:15Bert van Meurs Shares the New Late-breaking Results from the iMODERN Trial
-
Nov 3, 2025, 07:10Lisa Shea Shares Key Takeaways from NORD Summit 2025
-
Nov 3, 2025, 06:49Darshan Doshi on Results of iMODERN and ILIAS ANOCA Studies Presented at TCT 2025
-
Nov 2, 2025, 14:172019 ESC/EAS Guidelines for the Management of Dyslipidaemias Discussion with Lale Tokgözoğlu and Jeanine Roeters van Lennep
-
Nov 3, 2025, 09:13Claudio Carrubba on How Timing Truly Matters in Trauma Embolization
-
Nov 3, 2025, 08:46Rachel Lamerton and Colleagues on Activation of Platelets in Flow Cytometry
-
Nov 3, 2025, 04:56Nirupama Ramadas and Erica Sparkenbaugh on Thromboinflammation in SCD
-
Nov 2, 2025, 14:21Claude Franceschi: I Advise You to Understand the Hemodynamic Pathophysiology of Venous Diseases Rather than Blindly Applying Ablation Techniques or Venous Stent Placement
-
Nov 2, 2025, 14:15Krishna Aragam: Why are (DCM) and Heart Failure About Twice as Common in Individuals of Self-Identified Black Race?
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Oct 28, 2025, 06:49Lukas Gaats: Researchers Are Building Reproductive Organoids
-
Nov 3, 2025, 09:24Stephen Cornelissen: It’s Not Just About Emergencies — It’s About Everyday Care, Chronic Conditions and Hope
-
Nov 3, 2025, 06:57Maria Elisa Mancuso Reflects on 2025 Annual Congress of the Italian Association of Hemophilia Centres
-
Nov 3, 2025, 05:46Chandra Viswanathan: When Blood Safety Fails, We All Bleed - A Call for Reform and Responsibility
-
Nov 2, 2025, 14:17Anamaria B: Your Mother Still Runs Part of Your DNA
-
Nov 2, 2025, 10:57Paul Bolaji on Launching The First Centralised Nigerian National Stroke Registry